- Peter G. Schultz
- Fremont, CA
Ardelyx develops novel oral therapeutics to treat mineral metabolism and metabolic disorders.
Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. The Companyâ€™s molecules, whose systemic exposure is severely restricted, target transporters and receptors, modulating the uptake of nutrients or inducing secretion of key hormones to produce a therapeutic benefit in patients. The Companyâ€™s non-systemic products act from within the intestines to avoid potential side effects that could occur with systemic exposure. The Companyâ€™s lead product, RDX5791, a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and for prevention of excess dietary sodium absorption, a new treatment modality for high blood pressure. RDX5791 is in phase 2 for IBS-C and a dose-ranging/regimen study for inhibition of excess dietary sodium absorption. Ardelyx is also developing RDX002, a... See More
Current Team (11)Update
CEO & Board of Director
Vice President, Drug Development
Co-Founder and Director
Vice President, Chemistry
Sr. Director Regulatory Affairs and Quality Assurance
Vice President, Legal
Chief Business Officer
Funding Rounds (2) - $35MUpdate
34175 Ardenwood Blvd.
Fremont, CA 94555